Global Bacteriophage Therapy Market to about $60.71 million by 2030

The global bacteriophage therapy market size was nearly $42.1 million in 2021 and is set to increase to about $60.71 million by 2030 with a CAGR of nearly 4.5% between 2022 and 2030.

Due to the rise in multi-drug resisting bacterial infections, there exists a need for bacteriophage therapy in current times. Reportedly, bacteriophage therapy is one of the most effective anti-bacterial solutions available today. For the record, bacteriophage therapy also referred to as phage therapy is used for treating multi-drug resisting pathogens such as Enterobacteriaceae, Pseudomonas aeruginosa, and Acinetobacter baumannii. Moreover, the bacteriophage is used as a therapeutic agent for treating dysentery and cholera.

The growth of the global bacteriophage therapy market over the forecast timespan is subject to a rise in cases of foodborne diseases and a surge in the occurrence of antibiotic-resistant infections. In addition to this, the large-scale allocation of funds for improving healthcare infrastructure facilities will provide impetus to the expansion of the global market. Beneficial features such as low toxicity will prompt the growth of the global industry in the years ahead. Humungous use of bacteriophages in removing biofilms produced by various kinds of bacteria will boost global market trends.

However, the easy availability of alternative treatments for anti-microbe bacterial infections can hinder the expansion of the global bacteriophage market. In addition, huge costs related to bacteriophage treatment can put brakes on the surge of the bacteriophage industry across the globe. Moreover, a lack of awareness about the efficacy of bacteriophage therapy in treating bacterial infections in emerging economies can impede the expansion of the global industry. Nevertheless, a surge in the research & development activities related to bacteriophage treatment and technological breakthroughs will open new growth avenues for the global market.

The global bacteriophage therapy market is divided into product, application, route of administration, and region.

Based on the product, the global bacteriophage therapy market is sectored into phage probiotics and phage therapeutic. Moreover, the phage probiotics segment is set to dominate the expansion of the global market over the assessment period owing to the rise in food-borne infections. In addition to this, probiotics promote the intake of good bacteria and this feature has contributed lucratively towards the segmental surge.

In terms of application, the global bacteriophage therapy industry is segmented into respiratory infections treatment, skin infection treatment, gastroenterology, wound prophylaxis, and urogenital infection treatment segments. Moreover, the gastroenterology segment is slated to dominate the growth of the global market over the projected period due to the immense utilization of bacteriophage as dietary supplements for enhancing the gut health of people. The ability to treat gastrointestinal disorders with help of bacteriophage therapy will boost the segmental surge.

On basis of the route of administration, the global bacteriophage therapy industry is divided into oral and topical segments. Furthermore, the oral segment dominated the global bacteriophage therapy industry share in 2021 and is set to continue its domination even over the foreseeable future. The segmental growth can be attributed to ease of oral administration in patients, non-invasiveness, and cost-efficiency.

The North American bacteriophage therapy industry is predicted to witness exponential growth over the forecast period. The regional market expansion over the assessment timeframe can be credited to the rise in the cases of antibiotic resistance and surging demand for antibiotic substitutes in the countries such as Canada and the U.S.

Furthermore, the Asia-Pacific region is anticipated to be the fastest-growing bacteriophage therapy market during the assessment period. The regional market growth can be credited to the presence of strong healthcare infrastructure facilities in countries such as India and Japan and favorable government policies towards bacteriophage therapy for treating patients affected due to bacterial infections.

This review is based on a report by Zion Market Research, titled “Bacteriophage Therapy Market By Product (Phage Probiotics and Phage Therapeutic), By Route of Administration (Oral and Topical), By Application (Skin Infection Treatment, Gastroenterology, Wound Prophylaxis, Respiratory Infections Treatment, and Urogenital Infection Treatment), and By Region - Global and Regional Industry Overview, Market Intelligence, Comprehensive Analysis, Historical Data, and Forecasts 2022 – 2030.”- Report at https://www.zionmarketresearch.com/report/bacteriophage-therapy-market

Breakthroughs:

• In August 2021, Intralytix, Inc., a key player manufacturing bacteriophage-based products used for controlling bacterial pathogens in the environment, farming, food processing, and medical activities, was provided with a Fast Track NIH SBIR deal for creating a scale-independent artificial intelligence-based tool for manufacturing high titer bacteriophage for healthcare use.
• In December 2022, Armata Pharmaceuticals, Inc, a biotechnology company developing pathogen-specific bacteriophage therapy for antibiotic-resistant bacteria, concluded Phase 1b/2a clinical trials of its lead candidate referred to as AP-PA02, in cystic fibrosis subjects having chronic pulmonary P. aeruginosa infection. Such initiatives will increase the expansion of the global bacteriophage therapy industry.

Key participants in the global bacteriophage therapy industry include:

• PhagePro Inc.
• Enbiotix Inc.
• TechnoPhage SA
• Eligo Bioscience SA
• Armata Pharmaceuticals Inc.
• ContraFect Corporation
• Phagomed Biopharma GmbH.
• Eliava Biopreparations Ltd.
• Fixed-phage Ltd.
• Intodeworld Inc.
• Pherecydes Pharma
• BiomX Ltd.
• Adaptive Phage Therapeutics
• Intralytix Inc.
• Phagelux Inc.
• Nextbiotics
• InnoPhage Ltd
• Phi Therapeutics
• Locus Biosciences Inc.
• Micreos BV
• OPTIPHARM Co. Ltd.

The global bacteriophage therapy market is segmented as follows:

By Product

• Phage Probiotics
• Phage Therapeutic

By Route of Administration

• Oral
• Topical

By Application

• Skin Infection Treatment
• Gastroenterology
• Wound Prophylaxis
• Respiratory Infections Treatment
• Urogenital Infection Treatment

By Region

• North America
  • The U.S.
  • Canada
• Europe
  • France
  • The UK
  • Spain
  • Germany
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • GCC
  • South Africa
  • Rest of Middle East & Africa

About Us:

Zion Market Research is an obligated company. We create futuristic, cutting-edge, informative reports ranging from industry reports, the company reports to country reports. We provide our clients not only with market statistics unveiled by avowed private publishers and public organizations but also with vogue and newest industry reports along with pre-eminent and niche company profiles. Our database of market research reports comprises a wide variety of reports from cardinal industries. Our database is been updated constantly in order to fulfill our clients with prompt and direct online access to our database. Keeping in mind the client’s needs, we have included expert insights on global industries, products, and market trends in this database. Last but not the least, we make it our duty to ensure the success of clients connected to us—after all—if you do well, a little of the light shines on us.

Contact Us:

Zion Market Research
244 Fifth Avenue, Suite N202
New York, 10001, United States
Tel: +49-322 210 92714
USA/Canada Toll-Free No.1-855-465-4651
Email: sales@zionmarketresearch.com
Website: https://www.zionmarketresearch.com